Fluorouracil (5-FU), a commonly used anticancer agent, has potent cardiotoxicity that is mediated by vascular endothelial injury and vasospasm. Here, we report a patient demonstrating atrial fibrillation (AF), which was most likely induced by vasospasm mediated by 5-FU. A 69-year-old man presented with dysphagia and was diagnosed with advanced esophageal cancer. Frequent paroxysms of atrial fibrillation (AF) were observed during combination chemotherapy including 5-FU. AF was refractory to disopyramide, but was sensitive to antianginal agents (nicorandil and nitroglycerin transdermal patch). Coronary angiography performed within the chemotherapeutic period demonstrated moderate stenosis in the right coronary artery (RCA). Severe spasm at the proximal portion of the atrial branch in RCA was induced by provocation test using acetylcholine. Our case indicated that 5-FU predisposed vasospasm in RCA and the subsequent atrial ischemia may lead to AF. <Learning objective: Fluorouracil (5-FU), a commonly used anticancer agent, induces cardiac ischemic events and sometimes leads to the paroxysms of atrial fibrillation (AF). Coronary-dilating agents should be considered for the treatment of AF which occurs after the administration of 5-FU and is refractory to antiarrhythmic agents. ST-T segment. Transthoracic echocardiography showed no wall motion abnormalities, no left ventricular wall thickening, and no left atrial dilatation. Left ventricular ejection fraction was 64.3%, and the dimensions of interventricular septum, left ventricular posterior wall, and left atrium were 8 mm, 10 mm, and 26 mm, respectively. Considering that his performance status was satisfactory, biweekly DCF combination therapy (docetaxel 30 mg/m 2 day 1, 5-FU 800 mg/m 2 day 1-5, cisplatin 80 mg/m 2 day 1) was started. On day 6, asymptomatic AF was documented and terminated 1 h later. Anticoagulation was not performed due to a low CHADS2 score (1 point due to hypertension alone) and the high bleeding risk of the esophageal ulcer. Instead, a b-blocker (bisoprolol transdermal patch) was prescribed. Thereafter, sinus bradycardia was recorded prior to the 2nd course of chemotherapy and bisoprolol was discontinued. The chemotherapy regimen was changed to FP combination therapy (5-FU 800 mg/m 2 day 1-5, cisplatin 80 mg/m 2 day 1) due to an allergy to docetaxel. On day 4 of the 2nd course of chemotherapy, rapid AF was recorded with palpitations and mild oppressive pain in the chest. On day 5, syncope occurred due to rapid AF, showing a ventricular rate of 150 bpm ( Fig. 2(A) ). Intravenous disopyramide (50 mg) converted AF to a sinus rhythm after 3 s of sinus pause ( Fig. 2  (B) ), but atrial tachycardia occurred soon after ( Fig. 2(C) ).
Transdermal nitroglycerin patch was attempted as the patient had a chest discomfort and inferior leads (II, III, aVF) ECG showed slight ST-segment depression ( Fig. 2(D) ). Thirty minutes after placing the transdermal patch, AF was converted to a sinus rhythm. AF did not occur thereafter during the 2nd course of chemotherapy.
Dysphagia was exacerbated and lung metastasis showed progression based on the images of computed tomography (CT) performed after the completion of the 2nd course of chemotherapy. Hence, radiation (60 Gy/30Fr) accompanied by an FP regimen (5-FU 700 mg/m 2 day 1-5, cisplatin 50 mg/m 2 day 1) was performed as the 3rd course of anticancer therapy. AF recurred on day 4 during the 3rd course. AF sustained over the day 5, coronary angiography was performed, and 50% stenosis was observed at segment 2 of RCA as shown in Fig. 3(A) . A provocation test using 50 mg acetylcholine (ACh) induced diffuse spasms in RCA and severe (90%) spasms at the prior stenotic segment 2 accompanied with chest pain. Moreover, after the provocation test, the atrial branch of RCA showed 90% stenosis ( Fig. 3(B) ). Based on these coronary angiographic findings, nicorandil infusion and transdermal patches were attempted. Thirty minutes after administration of coronary dilating agents, sinus rhythm was restored without pause. In addition, the 4th FP-combination chemotherapy was successfully terminated without uncontrollable AF by readministration of transdermal nitroglycerin patch. After completion of whole chemotherapeutic regimen, AF did not recur leading to discontinuation of antianginal treatment.
Discussion
We present a patient with advanced esophageal cancer treated with chemotherapy including 5-FU, which most likely induced vasospasm in RCA leading to the paroxysms of AF. Despite AF being associated with cancer treatment that was resistant to antiarrhythmic agents, we could complete the cancer therapy safely using coronary dilating agents.
Although the exact mechanisms remain unclear, AF is observed in a maximum of 1.4% of cancer patients during a chemotherapy regimen including 5-FU [2] . The present case demonstrated dextrocardia and had coronary risk factors such as hypertension, current smoking, and chronic kidney disease. Indeed, coronary angiography performed on this patient demonstrated moderate organic stenosis in the proximal portion of the atrial branch in RCA ( Fig. 3(A) ). In addition, a provocation test using 50 mg ACh during the period of chemotherapy induced right coronary vasospasm, which included the atrial branch ( Fig. 3(B) ). Nicorandil infusion and transdermal patches restored sinus rhythm. These findings indicate that 5-FU caused vasospasm in the atherosclerotic RCA, and the subsequent atrial ischemia induced AF that was resistant to antiarrhythmic agents but sensitive to the coronary dilating agents.
The occurrence of AF in cancer patients is not rare and is due to comorbid inflammation, direct action of cancer, indirect action mediated by the autonomic nervous system, and the adverse effects of anticancer agents impairing coronary circulation [3] . Indeed, AF is a representative atrial arrhythmia, which is observed in patients with coronary artery disease (CAD). The prevalence of CAD in AF patients ranges from 17 to 46%, whereas the prevalence of AF in patients with CAD is low, up to 5% [4] . Our case strengthened literature reporting that acute cardiac ischemia sometimes underlies AF [5, 6] . Alasady et al.
reported atrial branch involvement is an independent predictor of new-onset AF observed after myocardial infarction [5] . Atrial ischemia creates arrhythmogenic substrates in animal models of atrial arrhythmia. Using canine models, Nishida et al. observed ectopic atrial activity and unstable multiple reentry circuits leading to AF in the ischemic border zone of infarcted atria undergoing atrial branch occlusion [6] . In humans, the sinus node artery as well as the right atrial branch originate from the RCA. ECG monitoring in this case demonstrated sinus pause with a maximum duration of 3 s and subsequent atrial tachycardia after the termination of paroxysmal AF (Fig. 2(B) ), which may reflect right coronary ischemia. Südhoff et al. demonstrated vasocontraction of brachial artery after administration of 5-FU and ameliorating effect of nitroglycerin [7] . Arterial vasocontraction induced by 5-FU administration may have aggravated ischemia leading to AF, which was successfully controlled by antianginal agents. 
Conclusion
The present case demonstrated coronary vasospasm induced by a provocation test using ACh, during the period of chemotherapy including 5-FU, and syncope due to rapid AF that was resistant to antiarrhythmic agents, but sensitive to antianginal agents. These findings indicate that 5-FU induced potent endothelial injury which caused vasospasm, and that atrial ischemia predisposes AF.
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